Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has informed BSE that its trading window for dealing in company securities will remain closed from October 1, 2025 until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2025. The closure applies to all designated persons, their immediate relatives, and connected persons covered under the company's insider trading code of conduct. A board meeting will be scheduled separately to consider and approve these Q2/H1 FY26 financial results, with a separate intimation to follow. The communication was signed by Executive Director Balasubba Reddy Mamilla (DIN: 01998852) on September 26, 2025.
This is a routine compliance filing with no direct impact on the stock price. It simply signals that the company's Q2 FY26 results announcement is approaching, which investors should monitor for actual financial performance.